A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Public ClinicalTrials.gov record NCT05306340. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Study identification
- NCT ID
- NCT05306340
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 373 participants
Conditions and interventions
Conditions
Interventions
- Giredestrant Drug
- Exemestane Drug
- Fulvestrant Drug
- Tamoxifen Drug
- Everolimus Drug
- LHRH Agonist Drug
- Dexamethasone Mouth Rinse Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2022 (Actual)
- Primary completion
- Jul 16, 2025 (Actual)
- Completion
- Oct 15, 2026 (Estimated)
- Last update posted
- Jun 17, 2026
2022 – 2026
United States locations
- U.S. sites
- 55
- U.S. states
- 28
- U.S. cities
- 50
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Oncology & Hematology, LLC | Anchorage | Alaska | 99508 | — |
| Arizona Oncology Associates, PC-CASA | Tucson | Arizona | 85711 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205-7199 | — |
| Alta Bates Summit Medical Center | Berkeley | California | 94704 | — |
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| TOI Clinical Research | Cerritos | California | 90703 | — |
| Women's Cancer Care | Fresno | California | 93710 | — |
| Scripps Health | La Jolla | California | 92037 | — |
| Los Angeles Hematology Oncology Medical Group | Los Angeles | California | 90017 | — |
| University of California, Irvine Medical Center | Orange | California | 92868 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32806 | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | 30060 | — |
| Summit Cancer Care PC | Savannah | Georgia | 31405 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Springfield Clinic | Springfield | Illinois | 62702 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Eastern Maine Medical Center | Brewer | Maine | 04412 | — |
| New England Cancer Specialists | Scarborough | Maine | 04074 | — |
| Anne Arundel Medical Center | Annapolis | Maryland | 21401 | — |
| University of Maryland Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Mercy Medical Center | Baltimore | Maryland | 21202 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Metro-Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota | 55416 | — |
| Oncology Hematology West, PC dba Nebraska Cancer Specialists | Omaha | Nebraska | 68103 | — |
| Renown Regional Medical Center | Reno | Nevada | 89502 | — |
| Memorial Sloan Kettering - Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| Memorial Sloan Kettering - Monmouth | Middletown | New Jersey | 07748 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| The Blavatnik Family ? Chelsea Medical Center at Mount Sinai | New York | New York | 10011 | — |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 10065 | — |
| Stony Brook University Medical Center | Stony Brook | New York | 11794 | — |
| SCRI Mark H. Zangmeister Center | Columbus | Ohio | 43219 | — |
| Oklahoma Cancer Specialists and Research Institute | Tulsa | Oklahoma | 74146 | — |
| St Charles Medical Center Bend | Bend | Oregon | 97701 | — |
| Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| UPMC Hillman Cancer Center - Magee-Women?s Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Abramson Cancer Center Chester County Hospital | West Chester | Pennsylvania | 19380 | — |
| McGlinn Cancer Institute at Reading Hospital | West Reading | Pennsylvania | 19611 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| West Cancer Center | Germantown | Tennessee | 38138 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Bedford | Texas | 76022 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology-Denton South | Denton | Texas | 76201 | — |
| Texas Oncology, P.A. - El Paso | El Paso | Texas | 79902 | — |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | — |
| Millennium Research & Clinical Development | Houston | Texas | 77090 | — |
| Texas Oncology P.A. | San Antonio | Texas | 78229 | — |
| Inova Fairfax Hospital | Fairfax | Virginia | 22031 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05306340, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 17, 2026 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05306340 live on ClinicalTrials.gov.